Joel Dudley, PhD

Joel Dudley, PhD

Biography

Director of Biomedical Informatics, Icahn School of Medicine at Mount Sinai

Dr. Dudley is a recognized leader in applying biomedical Big Data to healthcare and drug discovery. He currently holds positions as Associate Professor of Genetics and Genomic Sciences and Director of Biomedical Informatics at the Icahn School of Medicine at Mount Sinai. He also directs the newly formed Institute for Next Generation Healthcare at Mount Sinai. Prior to Mount Sinai, he held positions as Co- founder and Director of Informatics at NuMedii, Inc., one of the first companies to apply Big Data to drug discovery, and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University School of Medicine. His work is focused on developing and applying advanced computational methods to integrate the digital universe of information to build better predictive models of disease, drug response. He and his team are also developing pioneering methods to bring about a next generation of medicine that leverages advances in diagnostics, wearables, digital health to enable new approaches to precision medicine and scientific wellness. He has authored and co-authored more than 80 publications and his research has been featured in the Wall Street Journal, Scientific American, Forbes, and other popular media outlets. His recent work using a Big Data approach to identify sub-types of Type 2 diabetes was recently highlighted by NIH director Francis Collins on the the NIH Director’s Blog as a significant advance in precision medicine. He was named in 2014 as one of the 100 most creative people in business by Fast Company magazine. He is co-author of the book Exploring Personal Genomics from Oxford University Press, which is used as a text in personalized and precision medicine courses at universities worldwide. He holds an MS and PhD in Biomedical Informatics from Stanford University School of Medicine. Dr. Dudley serves on the Scientific Advisory boards of numerous startups and companies in biotech and healthtech.